[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568096":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":38,"centralContacts":42,"locations":47,"responsibleParty":64,"collaborators":33,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":33,"enrollmentInfo":77,"targetDuration":33,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":50,"whyStopped":33,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Part B oxytocin - Part A oxytocin - Part A Placebo - Part B Placebo","EXPERIMENTAL","Part A will investigate the recognition of facial emotions \\& body expressions in a cross-over design with a two-week wash-out period between both study visits. Part B will investigate the response of cortisol to acute psychosocial stress (TSST) with an eight-week wash-out period between both study visits. The order of group assignment is as follows: 1. Part B oxytocin, 2. Part A oxytocin, 3. Part A placebo, 4. Part B placebo",[13,14],"Drug: Oxytocin nasal spray","Other: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Part B oxytocin - Part A Placebo - Part A oxytocin - Part B Placebo","Part A will investigate the recognition of facial emotions \\& body expressions in a cross-over design with a two-week wash-out period between both study visits. Part B will investigate the response of cortisol to acute psychosocial stress (TSST) with an eight-week wash-out period between both study visits. The order of group assignment is as follows: 1. Part B oxytocin, 2. Part A placebo, 3. Part A oxytocin, 4. Part B placebo",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Part B Placebo - Part A Placebo - Part A oxytocin - Part B oxytocin","Part A will investigate the recognition of facial emotions \\& body expressions in a cross-over design with a two-week wash-out period between both study visits. Part B will investigate the response of cortisol to acute psychosocial stress (TSST) with an eight-week wash-out period between both study visits. The order of group assignment is as follows: 1. Part B placebo, 2. Part A placebo, 3. Part A oxytocin, 4. Part B oxytocin",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Part B Placebo - Part A oxytocin - Part A Placebo - Part B oxytocin","Part A will investigate the recognition of facial emotions \\& body expressions in a cross-over design with a two-week wash-out period between both study visits. Part B will investigate the response of cortisol to acute psychosocial stress (TSST) with an eight-week wash-out period between both study visits. The order of group assignment is as follows: 1. Part B placebo, 2. Part A oxytocin, 3. Part A placebo, 4. Part B oxytocin",[13,14],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Oxytocin nasal spray","Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.",[20,24,16,9],null,{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"Placebo","Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.",[20,24,16,9],[39],{"name":40,"affiliation":5,"role":41},"Mirjam Christ-Crain, Prof. Dr.","PRINCIPAL_INVESTIGATOR",[43],{"name":40,"role":44,"phone":45,"phoneExt":33,"email":46},"CONTACT","+41 61 328 70 80","mirjam.christ-crain@ubs.ch",[48],{"facility":49,"status":50,"city":51,"state":33,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":56,"coordinates":57},"Point",[58,59],7.57327,47.55839,{"lat":59,"lon":58},[62,63],{"name":40,"role":44,"phone":45,"phoneExt":33,"email":46},{"name":40,"role":41,"phone":33,"phoneExt":33,"email":33},{"type":65,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100568096","phase-2-effect-of-intranasal-oxytocin-on-emotion-recognition-and-acute-psycho-social-stress-induced-cortisol-increase-in-patients-with-central-diabetes-insipidus-and-healthy-controls-100568096",false,"NCT06676774","Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls","Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus (Arginine Vasopressin Deficiency) and Healthy Controls - the OxyMOTION-Study","OxyMOTION","Inclusion criteria healthy controls\n\n1. Adult healthy volunteers\n2. Matched for age, sex, BMI, and oestrogen replacement\u002Fmenopause\u002Fhormonal contraceptives to patients.\n3. No medication, except hormonal contraception\n\nInclusion criteria\n\n1. Adult patients with a confirmed diagnosis of AVP deficiency based on accepted criteria6\n2. Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies.\n\nExclusion criteria\n\n1. Participation in a trial with investigational drugs within 30 days\n2. Active substance use disorder within the last six months\n3. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n4. Current or previous psychotic disorder (e.g., schizophrenia spectrum disorder)\n5. Pregnancy and breastfeeding within the last eight weeks",true,"ALL","18 Years",{"count":78,"type":79},42,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This study aims to investigate the potential beneficial effects of intranasal oxytocin compared to placebo on emotion recognition and acute psychosocial stress in patients with arginine vasopressin deficiency compared to matched healthy controls.",[85,86],"Arginine Vasopressin Deficiency","Diabetes Insipidus",[88],"intranasal oxytocin","2025-05-22",{"date":91,"type":92},"2025-05-23","ACTUAL",{"date":94,"type":92},"2025-05-16",{"date":96,"type":79},"2027-02",{"name":5,"class":6},1]